L. Zhang

Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802)

C. Zhou, Yi‐Long Wu, G. Chen et al. · Annals of Oncology · 2015 · 464 citations

Non-small-cell Lung Cancer, Medicine, Pathology +8

Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC)

G. Chen, J. Feng, Caicun Zhou et al. · Annals of Oncology · 2013 · 119 citations · Full text

Medicine, Cancer Management, Phase Iii +6

Predominance of Cryptococcus neoformans var. grubii multilocus sequence type 5 and emergence of isolates with non-wild-type minimum inhibitory concentrations to fluconazole: a multi-centre study in China

Xin Fan, Meng Xiao, S. Chen et al. · Clinical Microbiology and Infection · 2016 · 47 citations

Diagnostic Mycology, Multi-centre Study, Pathogenic Microbiology +8

Risk factors for lymph node metastasis in papillary thyroid microcarcinoma: Older patients with fewer lymph node metastases

L. Zhang, Jiali Yang, Qianqian Sun et al. · European Journal of Surgical Oncology · 2016 · 35 citations

Papillary Thyroid Microcarcinoma, Medicine, Thyroid Disease +7

FP13.04 KEYNOTE-042 3-Year Survival Update: 1L Pembrolizumab vs Platinum-Based Chemotherapy for PD-L1+ Locally Advanced/Metastatic NSCLC

Byoung Chul Cho, Yi‐Long Wu, G. Lopes et al. · Journal of Thoracic Oncology · 2021 · 28 citations · Full text